Stockwinners Market Radar for November 04, 2019 - Earnings, Upgrades downgrades, option trades, Best Stock Advisory Service

20:02 EDT SolarWinds expands its Ingram Micro distribution relationship - SolarWinds announced the expansion of its Ingram Micro distributor relationship. Tapping further into Ingram Micro's network as the distributor extends the SolarWinds market presence in the Asia-Pacific region. The expanded relationship will also support the availability and access to the full range of SolarWinds networking, IT systems, database management, and security technologies for Ingram Micro's customers. Ingram Micro will also be distributing the SolarWinds MSP product portfolio, including SolarWinds Remote Monitoring and Management, to its customers in Singapore, Hong Kong, Thailand, Indonesia, Malaysia, and the Philippines. In addition to distribution, Ingram Micro will be using the MSP portfolio to provide Network Operations Center services to their customers "to help them achieve scalability, provide new revenue opportunities, and to create an efficient service delivery resource."

18:48 EDT Volaris reports October traffic up 17.8% and capacity up 17.3% - Volaris reported October 2019 and preliminary year to date traffic results. In October capacity measured by ASMs, or Available Seat Miles, increased by 17.3% vs the same period of last year, with the demand measured by RPMs, or Revenue Passenger Miles, showing an increase of 17.8%. Volaris carried 1.9M passengers in total, or 18.1% increase vs the same period of last year, with a load factor increase of 0.4 pp vs the same period of last year, for a total of 85.8%.

18:30 EDT HCA Healthcare's Foster sells 19,477 common shares - In a regulatory filing, HCA Healthcare group president Jon M. Foster disclosed the sale of 19,477 common shares of the company at a price of $132.3462 on October 31.

17:53 EDT Bell-Boeing awarded $146.04M Navy contract modification for MV-22 upgrades - Bell-Boeing was awarded a $146,04M modification to a previously awarded cost-plus-fixed-fee, fixed-price-incentive-firm-target and firm-fixed-price contract. This modification exercises the option to upgrade nine MV-22 aircraft from the Block B to the Block C configuration, as well as planned maintenance intervals for eight MV-22 aircraft, in support of the common configuration-readiness and modernization, or CC-RAM, program. Work will be performed in Ridley Park, Pennsylvania and Fort Worth, Texas, and is expected to be completed in March 2022. FY18 and FY20 aircraft procurement and FY20 operation and maintenance funds in the amount of $146.04M will be obligated at time of award, $6,05M of which will expire at the end of the current fiscal year. The Naval Air Systems Command is the contracting activity.

17:43 EDT Mosaic raises FY19 synergy target for Mosaic Fertilizantes by up to $50M - The company expects to exceed its previously announced synergy target for Mosaic Fertilizantes of $275M in 2019, by up to $50M. In addition, the company announced a new target of $200M in incremental annual EBITDA growth through ongoing business transformation efforts beginning in 2020 and ending by 2022. The company accelerated development of the Esterhazy K3 potash mine by an additional year, allowing the closure of the K1 and K2 shafts and elimination of brine management costs by mid-2022, as well as lower cost of production.

17:33 EDT Sanofi says FDA approves Fluzone High-Dose Quadrivalent for older adults - The FDA has approved a supplemental Biologics License Application for Fluzone High-Dose Quadrivalent for use in adults 65 years of age and older. Fluzone High-Dose was approved by the FDA in 2009 as a trivalent influenza vaccine, including two influenza A strains and one influenza B strain. Fluzone High-Dose Quadrivalent contains an additional influenza B strain. Fluzone High-Dose Quadrivalent is given to people 65 years of age and older to help prevent influenza disease caused by influenza A and B strains contained in the vaccine. This approval is the final step toward the company's complete transition to quadrivalent influenza vaccines in the U.S. Fluzone High-Dose Quadrivalent will be made available for immunization efforts during the 2020-2021 influenza season. Sanofi Pasteur will continue to deliver and offer the trivalent formulation of Fluzone High-Dose through the end of the 2019-2020 influenza season.

17:29 EDT Mosaic CEO expects 'much stronger year' in 2020 - "While the challenging market environment has persisted longer than we had anticipated, the actions we are taking give us an improved platform to deliver value and shareholder returns," said Mosaic President and CEO Joc O'Rourke. "We are seeing volumes move in North America and believe that strong volumes will lead to improved pricing. We believe that the bottom of the market is in and that 2020 will be a much stronger year for Mosaic and the customers we serve."

17:28 EDT Uber says Q3 was best quarter ever for rides - Says putting ballot measure to California voters in November 2020. Says targeting EBITDA profitability by FY21. Says cash and cash equivalents were $12.7B, which was up $900M from the Q2 due to the sale of $1.2B of senior unsecured notes and the closing of the $1B investment in ATG. Says competition has been fierce is some Uber Eats markets. Says willing to exit Uber Eats markets with low return of investment. Says ATG will be testing in Dallas in early November. Says a lot of shares will be unlocked on Wednesday. Comments taken from Q3 earnings conference call.

17:23 EDT Mistras says seeing a weak Oil and Gas market - The company states: "Revenues and operating earnings were ahead of FY18 on a year to date basis through the first nine months, indicating a robust business. However, the strong momentum developed over the past two quarters encountered some headwinds coming into Q4 of 2019. The company is seeing a weak Oil and Gas market, and an overall Fall season that ended much sooner than anticipated. In particular, the company sees weaknesses in the Oil and Gas turnaround market that appears to be attributable to supply buildups earlier in the year, as well as refineries shifting resources to prepare for IMO2020. In addition, towards the middle of September 2019 and into October 2019, a note of caution unexpectedly arose amongst Oil and Gas customers, attributable primarily to increased macroeconomic uncertainty. It is the same note of caution that is being heard in various sectors, stemming from many factors, including trade tensions, negative European interest rates, and the slowdown in domestic GDP growth. Although the long-term outlook remains intact, these factors are clearly influencing current activity in the Oil and Gas market, resulting in pushouts of demand. Although the company feels very good about where it is and its outlook for the long term, this unexpected pause in the Oil and Gas end markets has created some immediate challenges, which will affect performance for the fourth quarter of 2019 and full year 2019."

17:04 EDT Taro Pharmaceutical board approves $300M stock buyback - Taro board approved a $300 million share repurchase of ordinary shares. The timing, amount and value of any shares repurchased will be determined based on the company's ongoing assessments of the capital needs of the business, the market price of its stock, general market conditions and other factors. Shares will be repurchased using the company's existing sources of liquidity and free cash flow generated in the future.

17:01 EDT Columbia Sportswear names Timothy Boyle acting chairman - Columbia Sportswear Company announced that, in accordance with prior actions by the company's Board of Directors, President and CEO Timothy P. Boyle will serve as Acting Chairman of the Board following the passing of Gertrude Boyle. The Board intends to consider and take action regarding the formal appointment of a new Chairman of the Board at its next regularly scheduled Board meeting in January 2020. In addition to her leadership role within the company, Boyle held a substantial number of shares of the company's common stock. As of April 1, 2019, Gertrude Boyle held 9.4 million shares of the company's common stock, representing approximately 14% of the total shares outstanding. It is anticipated that the executor of Boyle's estate will be Sarah A. Bany, a longtime member of the Board and the sister of Timothy P. Boyle. The company understands that Boyle's estate plans call for the disposition of assets (which may include shares of the company's common stock) primarily to charitable foundations founded by family members, as well as directly to family members. The company further understands that under current tax law, family charitable foundations receiving shares of the company's common stock would have up to five years to sell those shares, subject to any extensions. The company intends to work with the parties to ensure the orderly transition of share ownership over the coming years.

17:00 EDT WWE expands live event partnership with GEA through 2027 - WWE and the Saudi General Entertainment Authority, GEA, have expanded their live event partnership through 2027 to include a second annual large-scale event. WWE and GEA also continue to work towards the completion of a media agreement in the MENA region.

16:55 EDT Delek US increases quarterly dividend 3.5% - Delek US announced its board declared a regular quarterly cash dividend of 30c per share. This represents a 3.5% increase from its previous regular quarterly dividend. Shareholders of record on November 18 will receive this cash dividend payable on December 2.

16:48 EDT AT&T, RingCentral partner over Unified Communications as a Service Solutions - AT&T (T) is expanding its relationship with RingCentral (RNG), making AT&T Office@Hand a lead offer for UCaaS solutions as part of its broad Voice and Collaboration portfolio. Based on the RingCentral platform, AT&T Office@Hand brings extensive mobile-first voice, video, online meetings, messaging and team collaboration capabilities to businesses and vertical sectors worldwide. In addition, AT&T and RingCentral plan to jointly develop capabilities and technologies that will further integrate with AT&T's network. "Businesses, no matter the size, get better results when employees can communicate and collaborate freely and effectively wherever they are," said Roman Pacewicz, Chief Product Officer, AT&T Business. "We've seen great success with the AT&T Office@Hand solution. Together with RingCentral, we're able to deliver premium cloud-based communication solutions that help more businesses improve customer engagement, drive employee productivity and streamline operations."

16:43 EDT Revance backs FY19 expense guidance - The company states: "Revance reiterates its financial guidance provided in February 2019. Revance expects 2019 GAAP operating expense to be in the range of $173M to $185M and non-GAAP operating expense, which excludes depreciation and stock-based compensation costs, to be in the range of $148 to $158 million as driven by increased research and development expenditures and launch preparation activities. With five clinical programs and preparations to file the BLA underway, Revance anticipates 2019 non-GAAP research and development expense to be $93 to $100 million. With the successful capital infusion through partnering agreements in 2018 and an equity raise in January, management believes the company has adequate cash reserves to fund its current operations through 2020."

16:40 EDT Gulf Island Fabrication completes strategic review, to remain independent - Gulf Island Fabrication announced the completion of its previously announced review of alternative strategies that began in early May 2019 and was led by a special committee of the board with assistance from the board's financial advisor, Johnson Rice & Company. The review was designed to objectively evaluate alternative strategies for the company, including possible merger or sale transactions, among other things. The review has not resulted in a viable proposal. After careful consideration, the board determined that the interests of the company's shareholders are best served if the company remains independent and the board focuses on executing the company's existing business plan, which includes enhancing the company's resources, processes and procedures to improve competitiveness and overall project execution and consideration of organic and inorganic opportunities for growth.

16:36 EDT Leidos awarded $60M task order from Centers for Disease Control and Prevention - Leidos has been awarded a new task order by the Centers for Disease Control and Prevention to provide support services for the National Healthcare Safety Network. The single-award, time and materials task order has a one-year base period of performance, followed by four one-year options, and a total approximate value of $60M if all options are exercised. Work will be performed in Atlanta.

16:34 EDT DXC Technology acquires Bluleader, terms not disclosed - DXC Technology announced it has acquired Bluleader, an Australian consulting company focused on delivering Customer Experience solutions. "We are excited about expanding the reach of Bluleader into DXC's diversified client base, so that our employees are engaged in interesting, challenging and career-enhancing projects," said Robin Apfel, managing director, Bluleader. "This combination will enable us to leverage DXC's market presence, intellectual property and expertise to expand the size and scale of Bluleader as part of DXC Oxygen's Integrated Practice."

16:32 EDT Aaron's CEO calls Q3 'challenging' - "While the third quarter was challenging, both Progressive and the Aaron's Business accomplished key objectives, which we believe significantly improve our long-term prospects for growth. At Progressive, third quarter invoice growth of 18.6% modestly decelerated from the second quarter. However, we expect increased productivity from new and existing retailers to drive accelerating invoice growth in the fourth quarter. In the Aaron's Business, the team launched new sales and marketing programs, which resulted in the strongest delivery growth the business has experienced in many years but also led to a decline in collections performance as our stores adapted to the new program. Given the positive momentum we are seeing in both businesses, we remain optimistic that we can continue to deliver long-term earnings growth," said John Robinson, CEO.

16:29 EDT Aaron's lowers FY19 CapEx view to $90M-$100M from $100M-$120M

16:22 EDT RF Industries acquires Schroff Technologies - RF Industries announced it has acquired Schroff Technologies International, a privately owned Rhode Island-based manufacturer of products serving the high growth wireless, telecom, and cable markets.

16:22 EDT Western Midstream sees FY20 CapEx down 20%-30% vs. midpoint of 2019 guidance - For FY20: Adjusted EBITDA is expected to grow approximately 10% year-over-year. Maintenance capital is expected to remain largely consistent as a percentage of Adjusted EBITDA, compared to 2019.

16:19 EDT Magnolia Oil & Gas sees Q4 production similar to Q3 volume levels - The company said, "We expect our fourth quarter production to be similar as compared to third quarter volume levels. Total capital spending for drilling and completions is expected to decline slightly in the fourth quarter, and in keeping with our business model. As our overall well completions will be weighted more towards Giddings, we expect production in Giddings to increase about 10 percent sequentially during the fourth quarter."

16:18 EDT Endo announces CEO Paul Campanelli to retire - Endo announced that Paul Campanelli, President and CEO has notified the Board of Directors of his intention to retire and the Board is implementing its CEO succession plan. Campanelli has been appointed Chairman of the Board effective immediately and will also continue to serve as President and CEO until his successor is appointed. Roger Kimmel, who has served as Chairman of the Board, has been appointed Senior Independent Director. Kimmel replaces Dr. Sharad Mansukani, who is resigning from the Board due to other commitments, including his recent appointment as chairman of the board of another company. The Board is launching a process to identify Campanelli's successor. Campanelli will be actively involved in that process and will help facilitate a smooth transition. In addition, he will continue to serve as Chairman of the Board following the appointment of his successor.

16:16 EDT Ensign Group acquires three skilled nursing facilities in San Antonio, Texas - The Ensign Group, the parent company of the Ensign group of companies, announced that it acquired the real estate and operations of the following skilled nursing facilities in San Antonio, Texas: Hunters Pond Rehabilitation and Healthcare, a skilled nursing facility with 128 skilled nursing beds; Pecan Valley Rehabilitation and Healthcare, a skilled nursing facility with 124 skilled nursing beds; and Westover Hills Rehabilitation and Healthcare, a skilled nursing facility with 124 skilled nursing beds. The acquisitions were effective November 1.

16:14 EDT Shake Shack shares down 12% after earnings report - At time of writing, shares of Shake Shack are down $10.39, or 12.3%, to $73.91.

16:12 EDT Sterling sees 'significant boost' to 2020 profitability from Plateau - Sterling Construction said, "In early October, we closed on our acquisition of Plateau, a leading provider of large-scale site infrastructure improvement contracting services that serves primarily large, blue-chip customers in the e-commerce, data center, distribution center and warehousing sectors," remarked Mr. Cutillo. "This acquisition directly aligns with our strategic vision by diversifying Sterling into adjacent end markets with a focus on bottom line growth. Plateau not only positions us in exciting and quickly growing market segments, but also expands our geographic footprint into the highly attractive Southeastern United States. We expect this transaction to result in a significant boost to our profitability in 2020 and beyond and we are excited to ramp up our activities with the Plateau team."

16:11 EDT Hologic launches Definity Cervical Dilator - Hologic has launched the Definity cervical dilator, a "major advancement" for gynecological procedures that uses SureAccess balloon technology to access uterine cavities without a tenaculum, lessening patient discomfort and reducing risk of perforation during dilation. Using SureAccess balloon technology,1 the Definity dilator is designed to eliminate multiple passes and minimize false tracking, reducing injury to the cervix, even in patients with complex or challenging cervical anatomy.

16:10 EDT Ensign Group acquires three skilled nursing facilities - The Ensign Group, the parent company of the Ensign group of companies, announced that it acquired the real estate and operations of the following skilled nursing facilities: Treasure Hills Healthcare and Rehabilitation Center, a skilled nursing facility with 110 skilled nursing beds, located in Harlingen, Texas; Keller Oaks Healthcare Center, a skilled nursing facility with 146 skilled nursing beds, located in Keller, Texas; and Kirkwood Manor, a skilled nursing facility with 162 skilled nursing beds, located in New Braunfels, Texas. The acquisitions were effective November 1. Ensign expects these operations to be accretive to earnings in 2020.

16:09 EDT Revance completes Aspen-1 phase 3 enrollment - Revance announced it has completed patient enrollment of the company's pivotal ASPEN-1 Phase 3 clinical trial for its investigational drug candidate DaxibotulinumtoxinA for Injection, or DAXI, for the treatment of isolated cervical dystonia, a movement disorder affecting the neck. In total, 301 adult patients were enrolled at 60 sites across the U.S., Canada and Europe. Revance plans to announce topline results from the ASPEN-1 Phase 3 trial in the second half of 2020, and is currently enrolling patients in a Phase 2 trial for adult upper limb spasticity and a Phase 2 trial for plantar fasciitis. DAXI is an investigational product and not approved by the FDA.

16:08 EDT Cimarex Energy cuts FY19 E&D capital guidance view to $1.3B-$1.4B - Estimated 2019 exploration and development investment is $1.30B-1.40B, down four percent at the midpoint from guidance given in February. Midstream investments are estimated to total approximately $70M in 2019.

16:07 EDT Unum Therapeutics shifts focus to ACTR, BOXR product candidates - Unum Therapeutics (UMRX) announced a strategic shift to focus development on its ACTR and BOXR product candidates in solid tumors and supportive platform capabilities. ACTR707 was engineered for properties that optimize its function in solid tumors including increased proliferation, cytokine secretion, and persistence. With Unum's focus on developing therapies for solid tumors, the company will de-prioritize investment in its hematologic programs. Testing through the first four dose levels in the ongoing ATTCK-20-03 Phase 1 trial in non-Hodgkin lymphoma has now established proof-of-concept for ACTR707. Given favorable tolerability to date at relatively low doses, Unum is announcing plans to continue limited dose escalation to inform potential future development of the program in 2020. Separately, Unum and its partner, Seattle Genetics (SGEN) have suspended further dose-escalation of the ATTCK-17-01 Phase 1 trial of ACTR087 with SEA-BCMA in multiple myeloma pending a further review of this program. No dose-limiting toxicities, or DLTs, following ACTR087 administration were reported and no severe adverse events of cytokine release syndrome, or CRS, or neurologic events have been observed to date. Phase 1 ATTCK-34-01 Trial: ACTR707 combined with trastuzumab to treat advanced HER2+ solid tumor cancers. Five clinical sites are now activated to support the Phase 1 trial that is currently enrolling patients. Unum expects to report preliminary safety data from patients treated in the first dose cohort of the trial by the end of this year and to report safety and clinical response data from multiple dose cohorts in 2020. BOXR1030: Incorporating the GOT2 transgene and targeting GPC3+ solid tumor cancers. Unum's first product candidate selected from its Bolt-On Chimeric Receptor, or BOXR, platform, BOXR1030, continues to progress towards first-in-human clinical trials. BOXR1030 expresses a glypican-3, or GPC3, targeted chimeric antigen receptor, or CAR, and leverages the "bolt-on" transgene glutamic-oxaloacetic transaminase 2, or GOT2, to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism. Preclinical studies have characterized the mechanism of action of BOXR1030's bolt-on transgene with further details to be presented at the upcoming Society for Immunotherapy of Cancer conference during November 6-10, 2019. Based on recent progress, Unum now plans to file an investigational new drug (IND) application for BOXR1030 in late 2020, enabling subsequent clinical testing in GPC3+ cancers. BOXR Platform Expansion: Unum's BOXR platform was established over two years ago with the aim of discovering novel transgenes that can be co-expressed with chimeric-targeting receptors to improve the function of T cells in the solid tumor microenvironment. As part of its strategic shift to target solid tumors, Unum will be scaling up its BOXR platform capabilities with the objectives of: expanding the scope of biological mechanisms and transgenes in its proprietary BOXR library, enabling BOXR bolt-on applications for a broad range of immune cell therapies, including both autologous and allogeneic approaches and advancing new BOXR product candidates into the clinic. Phase 1 ATTCK-20-03 trial: ACTR707 combined with rituximab for relapsed/refractory non-Hodgkin lymphoma. As a preliminary update provided today for the six patients treated in Cohort 4, complete response was achieved at the first response assessment in two of six patients as of the October analysis, yielding a complete response rate of 40% in Cohorts 1 through 4. Of the eight complete responders, four remained in complete response at six months of follow-up, two remain in complete response but have not yet reached the six-month timepoint for evaluation, and two progressed before the six-month timepoint. In Cohorts 1 through 4, ACTR707 was well-tolerated in combination with rituximab. No DLTs, no adverse events of CRS, and no severe neurological adverse events including neurotoxicity have been reported as of the October 2019 cutoff. Further results will be presented at the American Society for Hematology Annual Meeting. Unum plans to enroll up to two additional cohorts (three to four patients per cohort) in the trial, escalating the maximum dose up to 180M ACTR707+ T cells. With patient screening and planned dosing underway, Unum plans to report preliminary results from this dose escalation during 2020. The ability to differentiate on both efficacy and safety relative to currently available therapies and those in development from these additional cohorts will drive a decision during 2020 whether to advance the program into an expanded dose cohort and potential pivotal studies. Phase 1 ATTCK-17-01 trial: ACTR087 combined with SEA-BCMA for relapsed/refractory multiple myeloma. Two additional cohorts of patients have been treated in the Phase 1 trial in 2019, escalating doses of the SEA-BCMA antibody to 2.0 mg/kg and of the ACTR087+ T cells to 50M. Unum and Seattle Genetics have suspended further dose-escalation of the trial and are reviewing the next steps with this program.

16:04 EDT Workday to acquire Scout RFP for $540M in cash - Workday and Scout RFP have signed a definitive agreement under which Workday will acquire Scout RFP in an all cash transaction. Under the terms of the definitive agreement, Workday will acquire Scout RFP for consideration of approximately $540M in cash, subject to adjustments. The transaction is expected to close in Q4 of Workday's fiscal year 2020, ending January 31, 2020, subject to the satisfaction of customary closing conditions, including required regulatory approval.

15:50 EDT Nasdaq halts Golden Bull Limited for additional information requested - Nasdaq Stock Market announced that trading was halted today in Golden Bull Limited (DNJR) at 15:12:49 p.m. Eastern Time for "additional information requested" from the company at a last sale price of $0.3996. "Trading will remain halted until Golden Bull Limited has fully satisfied Nasdaq's request for additional information," Nasdaq stated.

15:28 EDT TV Time-UTA study sees disparity in consumer awareness for streaming services - A new study called "Beyond the Big Three", was jointly conducted by TV Time and United Talent Agency's IQ data and analytics group this past September to better understand how consumers feel about this new streaming media choices. According to the study there is quire a bit of disparity in the level of consumer awareness of new streaming services coming to market currently. The study says in part: "We know that consumers are cutting the cord at an ever-increasing rate, but what remains unclear is how they feel about the wealth of OTT choices that will soon be available...With so many new entrants, this result suggests the supply of streaming media will soon exceed current consumer demand. As the first of the new services to hit the market, Disney+ (DIS) and Apple TV+ (AAPL) may be less impacted by this dynamic. However, those with launch dates further out may face more of an uphill battle to win new subscribers as they ramp up marketing..., it is not surprising to learn that the vast majority,70%, of respondents feel there will soon be too many streaming video choices...Clearly, there is consumer appetite for both library and original content. However, a lack of library content may put streamers like Apple TV+ at a disadvantage...Disney+ has the highest levels of awareness and intent to subscribe, a healthy mix of library and original content, and the advantage that its service arrives before most others. Other companies in the streaming space include Netflix (NFLX), Dish (DISH), Google's (GOOG, GOOGL), AT&T's (T)HBOYouTube, Comcast (CMCSA), Discovery (DISCA), Amazon.com (AMZN). Reference Link

14:35 EDT PG&E trading resumes

12:08 EDT Omeros sinks after CMS releases final rule on Medicare hospital payments - Shares of Omeros are down 15% in midday trading after the Centers for Medicare & Medicaid Services announced a final rule, with comment period, that revises the Medicare hospital outpatient prospective payment system - OPPS - and the Medicare ambulatory surgical center - ASC - payment system for Calendar Year 2020. As part of its final rule, the CMS stated: "Moreover, the results of a CMS study of cataract procedures performed on Medicare beneficiaries in the OPPS between January 2015 and July 2019 comparing procedures performed with Omidria to procedures performed without Omidria did not demonstrate a significant decrease in fentanyl utilization during the cataract surgeries in the OPPS when Omidria was used. Our results also did not suggest any decrease in opioid utilization post-surgery for procedures involving Omidria. At this time, we do not have compelling evidence to exclude Omidria from packaging after its current pass-through expires on September 30, 2020. We will continue to analyze the evidence and monitor utilization of this drug." Gregory Demopulos, chairman and CEO of Omeros, stated, "Omeros supports CMS' intention and Congress' mandate to remove incentives that lead to increased opioid use, and we are optimistic that CMS will recognize the clear and convincing evidence that packaging OMIDRIA does create such a perverse incentive. OMIDRIA can be readily accessed by veterans as well as commercially insured and Med Advantage patients. We look forward to working with CMS to reduce opioid use and improve patient care by ensuring long-term access to OMIDRIA for Medicare Part B beneficiaries. CMS stated in the final rule that it will continue to analyze the evidence in support of the benefits of OMIDRIA and monitor utilization of this drug, and Omeros intends to address CMS' OMIDRIA-related comments. Omeros also plans to continue its administrative and legislative efforts to secure ongoing separate payment for OMIDRIA beyond the drug's current pass-through extension. OMIDRIA continues to receive separate payment from CMS under its pass-through extension until October 1, 2020." In midday trading, Omeros shares are down $2.50, or 15%, to $13.71. Reference Link

12:01 EDT Under Armour falls -15.1% - Under Armour is down -15.1%, or -$2.86 to $16.05.

12:01 EDT Insperity falls -34.0% - Insperity is down -34.0%, or -$36.65 to $71.02.

12:01 EDT SM Energy rises 15.3% - SM Energy is up 15.3%, or $1.28 to $9.66.

11:31 EDT Immuron receives R&D tax concession refund from Australian government - Immuron Limited announced that under the Australian Government's Research and Development Income Tax Concession incentive program, the company has received a cash refund of A$0.53M for eligible research and development expenditure incurred during the 2019 Financial Year. This refund reflects the company's continual investment made in its research and development programs during the 2019 Financial Year to progress its pipeline programs as well as the continuous development of the company's existing Travelan / Protectyn programs. "We are grateful that the Australian Government is such a strong supporter of the development of early-stage biotechnology companies through the R&D Tax Concession initiative scheme," said Dr. Gary S. Jacob, CEO of Immuron. "This cash refund mechanism provides a non-dilutive way to help with the financing of our in-house programs. Immuron has an ambitious program underway to further the development of our unique hyperimmune bovine colostrum technology directed against gut-specific pathogenic organisms."

10:42 EDT McDonald's fired CEO Easterbrook can't work for rival for at least two years - In a regulatory filing, McDonald's disclosed details of its separation agreement with Stephen Easterbrook, who was separated from his officer and director positions with the company, as previously reported. The agreement provides that he will be eligible for the severance benefits contemplated by the company's benefit plans upon a termination of employment. "In consideration for such benefits, Easterbrook has agreed to a release of claims in favor of the company, to cooperate with the company following his termination and to various restrictive covenants, including nonsolicitation of employees and non-interference with business partners for two years post-termination and perpetual confidentiality and nondisparagement covenants. In addition, the separation agreement contains a two-year post-termination noncompetition covenant, which is six months longer and more expansive in scope than Mr. Easterbrook's existing noncompetition covenants," the filing stated. "Competitive Companies," as defined by the company's agreement, shall mean any company in the restaurant industry - whether informal eating-out or ready-to-eat - that competes with the business of McDonald's, including examples such as Arby's, BoJangle's, Burger King/Hungry Jacks, Caffe Nero, Checker's, Chick-fil-A, Chipotle, Costa, Culver's, Denny's, Domino's Pizza, Dunkin' Brands, Five Guys, Greggs, Hardee's, In-N-Out Burger, Jack-in-the-Box, Jamba Juice, Long John Silver's Quick Service Restaurant Holdings, Panera Bread, Papa John's, Popeye's Chicken, Potbelly, Q-doba, Quiznos, Seven-Eleven, Sonic, Starbucks, Subway, Tim Horton's, WaWa, Wendy's, YUM Brands, the filing noted.

10:12 EDT Abbott recalls CentriMag System due to pump, motor issues - Abbot is recalling their CentriMag System due to a calibration system error resulting from electromagnetic interference that may cause the pump to slow or stop, the console screen to blank, and various inaccurate alarms. If the pump slows or stops, the patient is at risk of service adverse health consequences such as stroke, severe organ damage or death. Forty-four injuries and one death were reported at the time when Abbot initiated the recall in August 2019, the FDA said in a notice posted on its website. The CentriMag System is intended to pump blood through a patient for up to six hours during open heart procedures. The FDA has identified this as a Class I recall, the most serious type of recall. Reference Link

10:03 EDT Focus Financial Partners announces ABG of Michigan to join Sentinel - Focus Financial Partners announced that it has entered into a definitive agreement under which Alliance Benefit Group of Michigan will join Focus partner firm Sentinel Benefits & Financial Group, based in Wakefield, Massachusetts. The transaction is expected to close in the first quarter of 2020, subject to customary closing conditions. Founded in 1969 and located in Bingham Farms, Michigan, ABG of Michigan works with almost 400 benefits and retirement plans representing over 30,000 participants, and provides best-in-class administration and record-keeping services. ABG of Michigan's wholly-owned subsidiary, ABG Portfolio Strategies, Inc., provides investment advisory services primarily for retirement plan assets. ABG of Michigan, will expand Sentinel's geographical reach, creating a premier "super-regional" retirement and benefits-focused financial services firm, and will position Sentinel's business for further growth in the Midwest.

09:47 EDT Kosmos rises 10.0% - Kosmos is up 10.0%, or 64c to $6.96.

09:47 EDT VelocityShares 3x Long Natural Gas ETN rises 13.0% - VelocityShares 3x Long Natural Gas ETN is up 13.0%, or $2.22 to $19.26.

09:44 EDT Under Armour says sees FY domestic sales 'down slightly' - Says: Moving to playing offense in 2020 vs. defense... Plans to amplify brand in 2020... Sees licensing business up in Q4... "Very happy" with performance in Asia-Pacific region. Kevin Plank says stepping away from CEO position was "my decision."

09:28 EDT General Electric teams up with BBAM for AirVault asset transfer system - General Electric Aviation (GE) has teamed up with BBAM Aircraft Leasing & Management to provide the AirVault asset transfer system across a fleet of 510 aircraft including Airbus (EADSY), Boeing (BA) and Embraer (ERJ) airplanes used by more than 90 airlines. The implementation is starting this month. BBAM will start using the system by December, followed by a six-month evaluation. The combination of GE's domain expertise in flight analytics and engine diagnostics to bring disparate data together and the digital leased asset transfer system capability will further enable web-based fleet maintenance across the aviation leasing market. The asset transfer system is a collaborative tool that streamlines and simplifies the way that leased asset documentation is managed between airlines and lessors by allowing operators to organize records in accordance with industry standard. The system enhances the efficiency of lease returns several ways by helping operators harmonize and standardize files, perform collaborative document reviews with their lessor partners, and transfer files through an intuitive digital user interface which includes SPEC 2500 functionality.

09:18 EDT HP Inc., Adobe announce collaboration for 3D production technology - HP Inc. (HPQ) and Adobe (ADBE) announced Project Captis, a collaboration between HP and Adobe to develop and deliver an end-to-end product that can transform physical materials into digital 3D materials, equipping users with workflow efficiency gains while helping reduce time and costs. Project Captis takes advantage of Z by HP technology and Adobe Substance Alchemist software to take creative workflows to the next level. HP and Adobe plan to deliver Project Captis to partners across various industries, including game development, ecommerce, architecture and fashion, among others. Project Captis kicks off at Adobe MAX and will run through 2020.

09:15 EDT Bank of America to boost minimum hourly rate to $20 from $17 in 2020 - Bank of America announced that it is accelerating the move from its current U.S. minimum hourly rate of pay of $17 to $20 by the end of the first quarter of 2020, more than a year earlier than originally planned. "As part of our commitment to being a great place to work, we are saying thank you, and sharing our success with our teammates who serve our clients and communities every day," said Sheri Bronstein, Chief Human Resources officer at Bank of America.

09:13 EDT AeroVironment awarded $6.41M Raven follow-on contract - AeroVironment announced it received a firm fixed-price contract valued at $6.41M from an existing Southeast Asian military customer on September 17 for additional Raven unmanned aircraft systems. Delivery is anticipated within 12 months. AeroVironment's Raven system is designed for rapid deployment and high mobility for applications requiring low-altitude intelligence, surveillance and reconnaissance. With a wingspan of 4.5 feet and weighing 4.2 pounds, the hand-launched Raven provides aerial observation, day or night, at line-of-sight ranges up to approximately 6.2 miles. With its stabilized gimbaled payload, the Raven delivers real-time color or infrared imagery to ground control and remote viewing stations.

09:10 EDT ORIX Corp acquires Hunt Real Estate Capital - ORIX Corporation announced that it has signed a definitive agreement to acquire Hunt Real Estate Capital, LLC, a subsidiary of Hunt Companies. "The acquisition combines the financial strength of ORIX USA and the complementary product offerings of ORIX Real Estate Capital brands, Lancaster Pollard and Red Capital Group, with Hunt Real Estate Capital's strong presence in the multifamily industry. Upon closing, 15-year industry veteran James Flynn, Hunt Real Estate Capital's President and Chief Investment Officer, will be the CEO of the combined entity."

09:09 EDT GSE Systems, INL awarded DOE grant to develop solutions for advanced reactors - GSE Systems announced that the U.S. Department of Energy, or DOE, has awarded GSE and Idaho National Laboratory, or INL, a grant to develop dynamic procedures and decision-support solutions for advanced reactors. The grant is aimed towards developing and commercializing a system with the functionality to revolutionize operator and system efficiency, as compared to existing paper-based processes. The new technology aims to address a variety of industry challenges, including barriers to adoption, and the large number of procedures and data architecture required to address advanced reactors that feature increased levels of automation, sensors and instrumentation. By leveraging GSE's highly specialized expertise and technology in control room and plant simulators, software development, and nuclear operations procedures and INL's expertise in human factors, computer-based procedures, and operator decision support, power plant operators will be able to greatly reduce time spent on administrative tasks and increase efficiencies. The system will utilize dynamic procedure decision support for control room operations, emphasizing data analytics and monitoring of plant data, as well as intuitive user interfaces and functionality.

09:07 EDT Acadia appoints Ponni Subbiah CMO - Acadia announced the appointment of Ponni Subbiah as senior VP, global head of medical affairs and CMO. Subbiah will report to Serge Stankovic, Acadia's president and be responsible for corporate medical affairs including medical strategy, scientific communications and medical science liaison activities. Subbiah is a neurologist with over 20 years of experience in the pharmaceutical industry and global health sector. She has led the development and execution of medical and clinical research strategies in various therapeutic areas, including neurology, psychiatry, opioid addiction, pain, oncology, diabetes, urology, inflammation, respiratory and infectious diseases. Subbiah was most recently CMO for Indivior, with responsibility for pharmacovigilance and medical affairs globally.

09:06 EDT Callon urges stockholders to vote for acquisition of Carrizo - Callon Petroleum (CPE) issued a statement in response to a report by Institutional Shareholder Services, or ISS, regarding Callon's all-stock acquisition of Carrizo Oil & Gas (CRZO). Statement included: Callon strongly disagrees with ISS's recommendation and believes the following points are essential to understanding the merits of the transaction: Callon's stated strategy remains unchanged: As we have articulated in numerous quarterly investor calls, and on slide 20 of our recently filed investor presentation, Callon has been pursuing four strategic financial objectives: increase cash return on invested capital, generate free cash flow, reduce leverage and maintain a long-term focus. This transaction clearly advances each point of Callon's strategy. Scale is critical in an evolving industry landscape: As the shale industry turns from acreage acquisition to manufacturing mode, the efficiencies gained from large pad development and simultaneous operations are increasingly important for achieving a competitive cost structure.

09:04 EDT Eli Lilly, Boehringer Ingelheim modernise alliance - Boehringer Ingelheim and Eli Lilly and Company will modernise their current alliance as of 1 January 2020 and focus its combined expertise and investment on the continued development and commercialisation of Jardiance in type 2 diabetes, heart failure, and chronic kidney disease. Trajenta and Basaglar continue to be part of the Alliance, with primary responsibility for development and commercialisation led by the innovator company. Boehringer Ingelheim will continue as strategic lead for Trajenta, and Lilly for Basaglar. Under the amended and restated agreement, there will be a revised margin sharing structure for ongoing payments starting 1 January 2020. There are no changes to Lilly's 2019 financial guidance or 2020 financial goals as a result of this amendment. The specific impact on the upcoming year will be incorporated into Lilly's 2020 guidance, currently scheduled to be issued on 17 December 2019. The net result of the revised margin sharing structure is not expected to be financially material over the duration of the agreement.

09:04 EDT Akari Therapeutics exploring pivotal trial designs for nomacopan for BP - The company said, "Phase II trial results with nomacopan were presented at the 28th European Academy of Dermatology and Venereology Congress on October 10, 2019. Four of the six patients were classified as at the upper limit of moderate BP. The four patients saw a rapid and significant improvement in symptoms, with a mean 63% decline in Bullous Pemphigoid Disease Area Index score and mean 68% decline in blister score by day 42, with either no or minimal early steroid treatment. The data showed nomacopan's potential as monotherapy with the additional potential benefit of reducing steroid use which has multiple adverse effects. During the third quarter of 2019, the FDA granted orphan drug designation for nomacopan for the treatment of BP. The company is now exploring pivotal trial designs."

09:01 EDT Delta Air Lines reports October traffic up 5.2%, capacity up 5.1% - Load factor of 85.6% was up 0.1 pts.

08:56 EDT Broadcom completes acquisition of Enterprise Security business of Symantec - Broadcom (AVGO) announced that it has completed its acquisition of the Enterprise Security business of Symantec (SYMC). ymantec's Enterprise Security business will now operate as the Symantec Enterprise division of Broadcom and will be led by Art Gilliland as SVP and General Manager. Gilliland most recently served as General Manager of Symantec's Enterprise Security business where he oversaw the Enterprise Security product and engineering teams, Enterprise Security Worldwide Sales and the Enterprise Security customer support organization. He brings more than 20 years of experience in the security software industry.

08:52 EDT Jones Soda announces partnership with Harlan Fairbanks - Jones Soda has entered into an agreement with Harlan Fairbanks to distribute Jones fountain and frozen slush products across Canada and select markets in the United States. Beginning in early 2020, Harlan's will offer Jones' signature customized, branded equipment, along with handling the distribution of Jones fountain and frozen slush syrups. In addition to its national footprint across Canada, Harlan's has a strong presence in Alaska and Washington state, which are core markets for Jones' bottle business and its growing fountain business.

08:50 EDT Indosat Ooredoo selects Synchronoss DXP for user experience - Synchronoss Technologies announced that Indosat Ooredoo has chosen the Synchronoss Digital Experience Platform to deliver a unified, interconnected user experience for customers across all of its engagement channels. The Synchronoss platform will also support Indosat Ooredoo's "future digital economy ecosystem" project, a nationwide initiative to encourage collaboration and develop new ideas, products and use cases involving IoT technology to help drive economic growth.

08:47 EDT Aeglea BioTherapeutics appoints Ravi Rao as CMO, Michael Hanley as CCO - Aeglea BioTherapeutics (AGLE) announced two additions to its senior management team. The Company welcomes Dr. Ravi M. Rao as chief medical officer and Michael C. Hanley as chief commercial officer. Rao joins Aeglea from GlaxoSmithKline (GSK) where he served as Vice President, Global Medical Affairs Head, Immunology and Specialty Franchise, leading programs across a number of emerging disease areas. Hanley was previously Vice President and U.S. Chief Commercial Officer for Esteve Pharmaceuticals.

08:45 EDT Itamar Medical announces WatchPAT inclusion in BSC, BCBS FEP policies - Itamar Medical announced that Blue Shield of California and the Blue Cross Blue Shield Federal Employee Plan have included WatchPAT as a covered home sleep apnea diagnostic test. The Company also announced the release of the U.S. Centers for Medicare & Medicaid Services 2020 Fee Schedule which is the second year of a 3-year proposed plan by CMS to reevaluate reimbursement in home sleep apnea diagnostic codes. The changes made in the 2020 Fee Schedule are expected to continue to support and expand the broad use of its WatchPAT technology. In October 2019 both BSC, a health plan that covers approximately 3.7 million lives, and BCBS FEP, a health plan that covers approximately 5.3 million lives, updated their policies to include WatchPAT based on the PAT technology with oximetry and actigraphy, as a covered home sleep apnea diagnostic test. This inclusion of WatchPAT and PAT technology follows an assessment of Diagnosis and Medical Management of Obstructive Sleep Apnea Syndrome recently released by Blue Cross Blue Shield Association Evidence Street.

08:40 EDT Brookfield closes $9B global private equity fund - Brookfield Asset Management Inc. (BAM) announced the closing of its latest flagship global private equity fund, Brookfield Capital Partners V with total equity commitments of $9 billion in the program. Based on strong investor demand, BCP V attracted total capital commitments exceeding the original $7 billion fundraising target. BCP V's predecessor fund closed in 2016 with $4 billion of total capital commitments. Investors in the Fund are a diverse group of institutional investors, including public and private pension plans, sovereign wealth funds, financial institutions, endowments and foundations, family offices, and private wealth investors. Brookfield Business Partners L.P. (BBU) has committed $3 billion to the Fund, underscoring the alignment of interests with other investors.

08:36 EDT Krystal Biotech plans on filing INDs on KB104, KB301 in 1H20 - The company said, "We are planning on filing an IND on KB104 for the treatment of Netherton Syndrome and an IND for KB301 in 1H 2020."

08:33 EDT Motorcar Parts subsidiary announces strategic partnership with OPAL-RT - Motorcar Parts announced its wholly owned subsidiary D&V Electronics, based in Woodbridge, Ontario, has established a strategic partnership with Montreal, Quebec-based OPAL-RT, combining technologies for electric motor R&D, testing and manufacturing applications. D&V's and OPAL-RT's technologies provide customers the ability to utilize both technologies in combination at any stage of R&D, testing and manufacturing of electric motor inverters used in automotive and other transportation applications, and, specifically, DC powertrains and associated components.

08:33 EDT X4 Pharmaceuticals appoints Derek Meisner, J.D., as General Counsel - X4 Pharmaceuticals announced the appointment of Derek Meisner, J.D., as General Counsel. Most recently, Meisner held the role of General Counsel at Genocea Biosciences.

08:32 EDT Insperity trading resumes

08:30 EDT CymaBay reaches target enrollment in ENHANCE global Phase 3 study - CymaBay Therapeutics announced achievement of the targeted 240 patient enrollment goal for ENHANCE, a global Phase 3 study evaluating seladelpar for patients with Primary Biliary Cholangitis. CymaBay is on track to complete full enrollment by the end of November. With more than 240 patients enrolled, ENHANCE is CymaBay's lead regulatory registration study evaluating the safety and efficacy of its investigational drug, seladelpar, for patients already diagnosed with PBC who have been using ursodeoxycholic acid, but have not achieved the recommended treatment goal or cannot tolerate UDCA. ENHANCE is a 52-week, placebo-controlled, randomized study conducted in over 20 countries.

08:22 EDT MarketAxess completes acquisition of LiquidityEdge - MarketAxess Holdings has completed its previously announced acquisition of LiquidityEdge, a leading provider of an electronic U.S. Treasuries marketplace. The acquisition was completed on November 1, 2019 following approval from the necessary regulatory authorities. The purchase price is approximately $150 million, including $100 million in cash and 146,450 shares of MarketAxess common stock, subject to customary purchase price adjustments.

08:21 EDT Foamix announces publication of AMZEEQ topical foam long-term safety data - Foamix Pharmaceuticals announced the peer review publication of the long term open label safety portions of studies FX2014-04 and FX2014-05 in the Journal of Clinical and Aesthetic Dermatology. Studies 04 and 05 were conducted by Foamix to support the New Drug Application submission of AMZEEQ topical foam, which was approved by the U.S. Food and Drug Administration for the treatment of inflammatory lesions of non-nodular moderate to severe acne vulgaris in patients 9 years of age and older. Highlights from the Long-Term Safety Program: The open-label safety portions of Studies 04 and 05 enrolled a total of 657 patients, all of whom had completed 12 weeks of AMZEEQ topical foam, 4% or vehicle treatment in the preceding double-blind phases of these studies. Patients continued for up to an additional 40 weeks of open-label treatment with AMZEEQ. Of those enrolled in this safety study, 291 completed a total of 52 weeks of therapy. The key findings from the study are as follows: Subject satisfaction with AMZEEQ treatment remained high when re-assessed at Week 52 which was consistent with scores obtained at Week 12. Application site adverse events occurred in less than 2% of patients during the additional 40 weeks of open-label treatment with AMZEEQ. In the assessment of facial dermal tolerability at Week 52, more than 95% of patients had "none" or "mild" signs and symptoms, and no severe local tolerability scores were recorded. Non-dermal adverse events were comparable in type and frequency with those reported during the double-blinded portions of each study. The most frequently reported treatment-emergent adverse event was nasopharyngitis. No serious drug-related adverse events were reported.

08:19 EDT CNH Industrial acquires K-Line Ag, terms not disclosed - CNH Industrial announced its agreement to acquire the Australian agricultural implement manufacturer K-Line Ag. This acquisition will add key tillage and residue management equipment, which is key to ensuring optimal seedbed preparation, fundamental for productive yields, and will further enhance the crop production portfolios of Case IH and New Holland Agriculture, the global agricultural equipment brands of CNH Industrial. K-Line has become the number one tillage manufacturer in Australia by designing robust and reliable products for some of the world's harshest soil conditions.

08:18 EDT Global Blood Therapeutics announces new employment inducement grants - Global Blood Therapeutics announced that on November 1, 2019, the compensation committee of GBT's board of directors granted 72 new employees options to purchase an aggregate of 55,100 shares of the company's common stock with a per share exercise price of $49.72 and restricted stock units for an aggregate of 144,600 shares of the company's common stock. All of the above-described awards were made under GBT's Amended and Restated 2017 Inducement Equity Plan (the Plan).

08:15 EDT China Rapid receives NYSE's approval for its Business Transformation Plan - China Rapid Finance announced receipt of a letter from the NYSE accepting the Business Transformation Plan submitted by XRF on September 13. The Plan lays out a roadmap for addressing and achieving the NYSE's continued listing criteria. The Company believes its Plan offers a reasonable and achievable path toward restructuring its business and eventually resuming robust growth, serving the emerging consumer credit market in China. As part of the Plan, XRF intends to file Form 20-F for the fiscal year ended December 31, 2018, on or before November 15.

08:13 EDT Sprint CEO says merging with T-Mobile 'best outcome for all consumers' - "I am proud of the resiliency of the Sprint team as they work to deliver results in a challenging environment," said Sprint CEO Michel Combes. "However, I remain convinced that merging with T-Mobile and building one of the world's most advanced 5G networks is the best outcome for all consumers, employees, and shareholders."

08:12 EDT Entrada Therapeutics appoints Nathan Dowden as COO - Entrada Therapeutics announced the appointment of Nathan J. Dowden as COO. Dowden was most recently Senior Vice President of Strategy and Corporate Development at Rubius (RUBY) Therapeutics and joins Entrada with almost 30 years of strategy, investment and operational experience in the healthcare field. While serving as Senior Vice President of Strategy and Corporate Development at Rubius, Dowden worked to develop and integrate the company's platform, capital formation and communication strategy to support the organization's evolution from an early discovery company into a clinical development organization. Prior to joining Rubius, Dowden served as Managing Director at the Huron Consulting Group (HURN).

08:11 EDT Insperity trading halted, news pending

08:10 EDT Glass Lewis recommends stockholders vote for Velan Capital board nominees - Velan Capital, one of the largest stockholders of Progenics, announced that proxy advisory firm Glass Lewis has recommended that stockholders vote on the Green consent card in support of Velan's director nominees, Gerard Ber, Eric Ende, Heinz Mausli and David Mims, to constitute a majority of the Progenics board. Glass Lewis also recommended the removal of CEO Mark Baker and David Scheinberg from the board. Institutional Shareholder Services, or ISS, also recently recommended stockholders support Velan's case for change by voting on the Green consent card in support of its director nominees. Additionally, the third proxy advisory firm, Egan-Jones, has recommended that stockholders vote for all Velan nominees on the Green consent card. Bala Venkataraman, managing partner of Velan Capital, issued the following statement: "We are pleased Glass Lewis agrees with us that a majority of the Progenics Board must be refreshed. In our view, a clear mandate for change now exists - with all three proxy advisory firms, including Glass Lewis, ISS and Egan Jones, supporting our case for change at the Company..."

08:08 EDT Penn Virginia appoints Russell Kelley Jr. as CFO - Penn Virginia Corporation (PVAC) announced that Russell T. Kelley, Jr. has been named Senior Vice President, Chief Financial Officer and Treasurer effective November 13, 2019. Kelley previously served as Chief Financial Officer of Extraction Oil & Gas, Inc. (XOG).

08:06 EDT AM InvestCo Italy sends termination notice on purchase agreement for Ilva - AM InvestCo Italy sent to Ilva's Commissioners a notice to withdraw from, or terminate, the agreement for the lease and subsequent conditional purchase of the business of Ilva S.p.A. and certain of its subsidiaries, closed on 31 October 2018. The Agreement stipulates that, in the event that a new law affects the environmental plan for the Taranto plant so as to materially impair the ability to operate it or to implement its industrial plan, the Company has a contractual right to withdraw from the Agreement. Effective on 3 November 2019, the Italian Parliament has removed the legal protection necessary for the Company to implement its environmental plan without the risk of criminal liability, thus justifying the withdrawal notice. In addition, the decisions issued by the criminal court of Taranto bind the Ilva extraordinary Commissioners to complete certain prescriptions by 13 December 2019 - a term the Commissioners themselves deemed impossible to meet - failing which blast furnace number 2 will be shut down. Such prescriptions should also reasonably and prudentially be applied to the other two blast furnaces at the Taranto plant. The shutdown would make it impossible for the Company to implement its industrial plan, operate the Taranto plant and, generally, perform the Agreement. Other serious occurrences, independent of the Company's will, have also led to a situation of legal and operational uncertainty that has further significantly impaired the ability to carry out the necessary operations at Ilva and operate the Taranto plant. All the mentioned circumstances also entitle the Company to terminate the Agreement under the applicable provisions and principles of the Italian Civil Code. In accordance with the content of the Agreement, the Company has asked the extraordinary Commissioners to take responsibility for Ilva's operations and employees within 30 days from the receipt of the notice of withdrawal and termination.

08:06 EDT Eros acquires international distribution rights to 4 Bollywood films - Eros International announced that it will release four Hindi language films across different genres later this year in several overseas markets including the UK, US and Middle East. "First to release will be the romantic action film titled 'Marjaavaan' on the 15th of November, directed by Milap Zaveri, starring Sidharth Malhotra, Riteish Deshmukh, Tara Sutaria and Rakul Preet Singh. Produced by T-Series and Emmay Entertainment, the film is a dramatic, violent and action-packed love story. The second film to be distributed will be 'Pagalpanti', which is scheduled to release on the 22nd of November. The forthcoming film is a comedy caper directed by filmmaker Anees Bazmee and produced by T-Series and Panorama Studios. The story of the film revolves around a group of Indian tourists on vacation that turns into a patriotic mission. The comedy stars Anil Kapoor, John Abraham, Ileana D'Cruz and Arshad Warsi. Closely followed will be two other releases, one titled 'Pati Patni Aur Woh' and the other, 'The Body'. The two starkly different films are scheduled to release simultaneously on the 6th of December. The former is a remake of a cult Bollywood film of the same name. Produced by T-Series and directed by Mudassar Aziz, the highly awaited film stars Kartik Aaryan, Ananya Panday and Bhumi Pednekar. 'The Body' is a thriller mystery inspired by its Spanish antecedent. Produced by Viacom18 Motion Pictures, the film is headlined by Emraan Hashmi, Rishi Kapoor, Vedhika and Sobhita Dhulipala."

08:04 EDT Phreesia appoints Randy Rasmussen as Chief Accounting Officer - Phreesia (PHR) announced the appointment of Randy Rasmussen as Chief Accounting Officer, reporting to Tom Altier, Phreesia's CFO, effective November 1. Most recently, he was a Senior Vice President and Controller with Medidata Solutions (MDSO).

08:04 EDT Sprint reports Q2 postpaid net additions of 273,000 - Reports Q2 data device net additions of 364,000 were partially offset by phone net losses of 91,000. Average postpaid accounts were stable sequentially and year-over-year for the second consecutive quarter.

08:03 EDT Pattern Energy to be acquired by CPPIB for $26.75 per share in cash

07:58 EDT Minerva expects top-line results for Phase 2b trial of MIN-117 in Q4 - The company said, "Enrollment has been completed in a Phase 2b trial of MIN-117 in the U.S. and Europe, with a total of 360 adult patients enrolled with moderate or severe major depressive disorder with anxious distress and without psychotic features. The Company expects top-line results from this trial in the fourth quarter of 2019. This trial is a 6-week, 3-arm, randomized, double-blind, placebo-controlled study to investigate the safety and efficacy of MIN-117. The primary efficacy endpoint is the change in the Montgomery-Asberg Depression Rating Scale total score from baseline to the end of the double-blind treatment period, and the key secondary endpoint is the change in the Hamilton-Anxiety Rating Scale over the same period."

07:58 EDT TriMas announces increased share repurchase authorization to $150M - TriMas announced that its Board of Directors increased the company's common stock share repurchase authorization to $150M. The previous authorization, approved in February, authorized up to $75M in share repurchases.

07:57 EDT Endava announces acquisition of Intuitus - Endava announced the purchase of Intuitu, headquartered in Edinburgh, Scotland. Intuitus is a leading independent provider of technology and digital due diligence, and other technology advisory services to Private Equity clients. "The acquisition of Intuitus will enhance Endava's capability and accelerate our penetration of this market segment. Technology is becoming ever more crucial to the investment thesis of Private Equity firms as they seek value transforming business change in their portfolio. They need to identify disruption opportunities and require external expertise to navigate the rapidly changing technology landscape."

07:55 EDT Pattern Energy trading halted, news pending

07:51 EDT Tomkins agrees to sell Lamons business to First Reserve for $135M in cash - TriMas announced that TriMas Company, a wholly-owned subsidiary of TriMas Corporation, has entered into a definitive agreement to sell its Lamons business to First Reserve, a private equity firm focused on energy investing, for $135 million in cash, subject to customary working capital and purchase price adjustments. The closing is expected to occur by the end of the first quarter of 2020, and remains subject to customary regulatory approvals and closing conditions.

07:47 EDT HubSpot acquires PieSync, terms not disclosed - HubSpot announced that it has acquired PieSync, the fastest-growing real-time intelligent customer data synchronization platform. PieSync is one of the only iPaaS offerings that provides both a current and historical two-way sync of customer data that operates in the background, freeing up precious time so companies can focus their energy on their customers instead of their software.

07:45 EDT OpGen says Curetis' Ares Genetics launches AI-powered molecular AST - OpGen reported an update on the business of Curetis GmbH, the other party to the planned business combination with OpGen. On October 28, 2019, Curetis, N.V. announced that its wholly-owned subsidiary Ares Genetics has launched an early access program for its novel, artificial intelligence powered, next-generation sequencing based molecular antibiotic susceptibility test. Information on antibiotic susceptibility of pathogens is of utmost importance for clinical practice, epidemiology and public health purposes as well as for the development of pharmaceutical products in the infectious disease sector. Ares Genetics therefore has developed a molecular AST that will be marketed under the brand name ARESupa - Universal Pathogenome Assay. It is an expanded version of the NGS-based ARESupa initially launched in August 2019 for the identification of pathogens and resistance genes. The new version of the ARESupa is now capable of also accurately predicting antibiotic susceptibility via AI-powered interpretation of high-throughput DNA sequencing data. Ares Genetics reports that it has received commercial orders for more than 1,000 ARESupa tests, an order volume exceeding EUR 500,000. Together with advanced bioinformatics and AI services leveraging ARESdb for the diagnostics and pharma industry, as well as access to certain rights, Ares Genetics has contracted for and received orders amounting to more than 2 million Euro in 2019 to date. OpGen and Curetis entered into a definitive agreement to combine businesses on September 4, 2019. The closing of the transaction under such definitive agreement has not yet occurred and is subject to a number of significant closing conditions, including receipt of approval from the stockholders of OpGen, Inc. and the shareholders of Curetis, N.V. Until the closing occurs, each of OpGen and Curetis are operating as stand-alone businesses.

07:40 EDT ADMA Biologics announces acceptance to Plasma Protein Therapeutics Association - ADMA Biologics announced that it has been accepted as a member of the Plasma Protein Therapeutics Association as a North America Member effective January 1, 2020. Adam Grossman, President and CEO of ADMA, will join the PPTA North America Board of Directors.

07:37 EDT EyePoint announces addition of DEXYCU, YUTIQ to VA federal supply schedule - EyePoint Pharmaceuticals announced that it has signed an interim agreement with the U.S. Department of Veteran Affairs for DEXYCU and YUTIQ to be included on the Federal Supply Schedule, providing U.S. veterans and other federal government agencies with access to both products. The VA FSS contract will extend access to Eyepoint products to over nine million VA beneficiaries and others within the federal system. The final VA contract is expected to be executed in the next few months and have a five-year term.

07:33 EDT Genie Energy: Prism Solar receives additional purchase orders from JPMorgan - Genie Energy (GNE) announced that its solar manufacturing subsidiary, Prism Solar Technologies , has received additional purchase orders from JPMorgan Chase Bank (JPM) to supply solar modules for installation at JPMorgan Chase facilities nationwide. JPMorgan Chase and Prism Solar previously reached a module supply agreement pursuant to which Prism Solar was named Preferred Supplier for the 2017-2020 JPMorgan Chase Solar PV Installation Program for locations in the USA.

07:32 EDT Karyopharm expects topline data from Phase 3 portion of SEAL stduy in 2020 - Karyopharm previously reported positive results from the Phase 2 portion of the randomized, blinded Phase 2/3 SEAL study evaluating single-agent selinexor versus placebo in patients with previously treated, advanced unresectable dedifferentiated liposarcoma. Enrollment is currently ongoing in the Phase 3 portion of the SEAL study. Top-line data from the Phase 3 portion of the SEAL study are anticipated in 2020. Assuming a positive outcome on the primary endpoint of PFS, the Company intends to use the data from the SEAL study to support NDA and MAA submissions requesting approval for selinexor for patients with advanced unresectable dedifferentiated liposarcoma.

07:31 EDT Karyopharm expects to submit NDA for selinexor by end of 2019 - Following the positive results from the Phase 2b SADAL study that were first presented at the America Society of Hematology 2018 Annual Meeting and then updated in June at the 2019 International Conference on Malignant Lymphoma, Karyopharm expects to submit a New Drug Application to the FDA by the end of 2019 requesting accelerated approval for selinexor as a treatment for patients with relapsed or refractory DLBCL after at least two prior multi-agent therapies and who are ineligible for stem cell transplantation including CAR-T therapy. The Company also expects to submit an MAA to the EMA in 2020 requesting conditional approval for selinexor in the same indication. In addition to orphan drug designation, selinexor was granted fast track designation for this indication by the FDA in 2018.

07:29 EDT Karyopharm expects topline data from Phase 3 BOSTON study in early 2020 - Karyopharm's pivotal, randomized Phase 3 BOSTON study is progressing and patient enrollment was completed in January 2019. Top-line data are expected in early 2020 contingent upon the occurrence of progression-free survival events, the primary endpoint of the study. The BOSTON study is evaluating 100mg of selinexor dosed once weekly in combination with the proteasome inhibitor Velcade and low dose dexamethasone, compared to standard twice weekly Velcade and low dose dexamethasone in patients with multiple myeloma who have had one to three prior lines of therapy. Data from the BOSTON study, if positive, are expected to be used to support regulatory submissions to the FDA and EMA requesting the use of selinexor in combination with Velcade and dexamethasone in patients with multiple myeloma who have received at least one prior therapy.

07:27 EDT Regal Beloit announces new $250M share repurchase program - The Board of Directors on October 25 approved a new $250M share purchase authorization replacing the previous authorization.

07:25 EDT Trevena expects to report topline data from TRV250 PoC study in 2H20 - The company said, "Initiated TRV250 acute migraine proof-of-concept study. This is a single-dose, double-blind, placebo-controlled study with an enrollment target of approximately 120 migraine patients in a validated nitroglycerin provocation migraine model. Patients will be randomized before receiving a continuous NTG infusion, followed by administration of a 20 mg subcutaneous dose of TRV250 or placebo. The primary objective of the study is to determine target engagement, which will be measured as a reduction of sustained NTG-induced headaches. This study will also evaluate the overall safety of TRV250 and its ability to reduce symptomatic anxiety. The Company anticipates reporting topline data from this study in the second half of 2020."

07:22 EDT Trevena expects cash, cash equivalents to fund requirements into 3Q20 - Cash, cash equivalents, and marketable securities were $44.7 million as of September 30, 2019. The Company believes its cash, cash equivalents, and marketable securities as of September 30, 2019, together with interest thereon, to be sufficient to fund the Company's operating expenses, debt service, and capital expenditure requirements into the third quarter of 2020.

07:17 EDT UP Fintech subsidiary receives approval to conduct new businesses from FINRA - UP Fintech Holding announced that its wholly-owned subsidiary, US Tiger Securities, or USTS, received approval for conducting new businesses, including underwriting, private placements, mergers and acquisitions, mutual fund retailing, as well as selling group participant services from the Financial Industry Regulatory Authority, or FINRA, on October 16.

07:14 EDT Izea announces contract expansions with multiple Fortune 500 customers - IZEA Worldwide announced that it has expanded its relationships with multiple Fortune 500 customers. The company has signed a mid six-figure managed services contract with a leading global retailer to provide influencer marketing services, pushing their total annual commitment to nearly $1.5M. In addition, the company has signed six-figure expansions with two other leading global retailers, each focused on influencer marketing promotions for the holidays.

07:13 EDT Aveo Pharmaceuticals provides update after FDA meeting discussing TIVO-3 results - Aveo Pharmaceuticals provided a regulatory update following a meeting with the FDA to discuss results from the August overall survival, or OS, analysis of the TIVO-3 trial and the company's proposal to proceed with a new drug application, or NDA, for tivozanib. TIVO-3 is the company's Phase 3 randomized, controlled, multi-center, open-label study to compare tivozanib, the company's vascular endothelial growth factor receptor tyrosine kinase inhibitor, or VEGFR-TKI, to sorafenib in 350 subjects with highly refractory metastatic renal cell carcinoma, or RCC. The TIVO-3 trial was designed to address the FDA's concerns regarding the OS trend in the TIVO-1 trial. In the TIVO-1 trial, the company's initial RCC pivotal trial, the FDA found that the inconsistent progression free survival, or PFS, and OS results and imbalance in post study treatments made the trial results uninterpretable and inconclusive when making a risk-benefit assessment necessary for drug approval. The company previously announced that the TIVO-3 trial met its primary endpoint of demonstrating a significant improvement in PFS. The study also demonstrated a significant improvement in the secondary endpoint of overall response rate. The August analysis of the secondary endpoint of OS was the second prespecified interim OS analysis of the TIVO-3 trial, and showed an updated OS hazard ratio, or HR, of 0.99 at two years from the last patient enrolled in the study. In the FDA's preliminary feedback, based on its assessment of the totality of evidence presented to date, the FDA recommended that the company not submit an NDA at this time. The FDA stated that it remained concerned about the results of TIVO-3 in the context of the overall development of tivozanib. The FDA noted that the company's current interim OS results do not abrogate the FDA's concerns over detriment and that those results may worsen with final analysis at 263 events and that the median OS for tivozanib is worse than that of sorafenib. In view of the changing first-line treatment landscape as well as the FDA's continued concerns, the company informed the FDA that it intends to narrow its proposed indication to relapsed/refractory RCC. At the meeting, the FDA acknowledged AVEO's responses and reiterated its concerns about the survival information and the totality of data. The FDA noted that the choice to submit the data is the company's, and that a discussion with the Oncologic Drug Advisory Committee will likely be required. The FDA said that if AVEO wishes to proceed with a revised OS analysis in June 2020, AVEO should submit an updated statistical analysis plan, or SAP, with a planned OS update based on the projected number of events at that time. AVEO intends to submit to the FDA an update to the SAP for the final OS analysis consistent with these discussions, followed by an NDA submission in Q1 of 2020. AVEO expects to report the final OS analysis in June 2020 based on a May 1, 2020 cutoff, at which point the company estimates that the study will have reached approximately 263 OS events, as discussed with the FDA. The FDA and the company agreed that if the final analysis yields an OS HR above 1.00, the company will withdraw its NDA application.

07:12 EDT ICU Medical to acquire Pursuit Vascular for $75M - ICU Medical announced that it has entered into a definitive agreement to acquire Pursuit Vascular for $75M with an additional earnout payment potentially due in 2021. Pursuit Vascular is a privately-held medical device company with a primary focus on innovative catheter disinfecting products and technologies to reduce costly bloodstream infections and lower healthcare costs. Pursuit Vascular's primary product is the ClearGuard HD cap, which is used for the maintenance of hemodialysis catheters. Patients receiving dialysis treatments are at high risk of getting an infection because of the need to access their blood frequently. ClearGuard HD kills infection-causing bacteria and fungi inside of a hemodialysis catheter to help reduce infections. It is a safe, effective, and easy-to-use solution that has been shown in two large scale clinical studies to reduce bloodstream infections by approximately 70% when compared to current products. Pursuit Vascular's full-year 2019 annual revenues are estimated to be between $10M-$12M with margins comparable to the existing ICU Medical IV consumables business. The transaction will be funded with cash on hand and is not expected to have a material impact on the company's current adjusted EBITDA and adjusted EPS guidance for 2019.

07:10 EDT Obsidian Energy reaffirms FY19 production view 26,750boe/d-27,750boe/d

07:08 EDT Halozyme announces restructuring, to reduce headcount approximately 55% - Halozyme Therapeutics announced strategic actions to reposition the company with a focus solely on its ENHANZE drug delivery technology. In order to implement this strategic shift, Halozyme will immediately initiate an organizational restructuring to halt development activities for PEGPH20 and close its oncology operations. As a result, Halozyme expects the following: Headcount will be reduced by approximately 55%, or approximately 160 positions, with over 80% of the reduction completed in early January 2020. Restructuring and other cost saving efforts will result in savings of $130M-$140M in 2020 compared with the company's most recent guidance for 2019 operating expenses excluding cost of goods sold. Upon completion of the restructuring and after booking all related one-time charges, Halozyme anticipates becoming a sustainably profitable company beginning in the second quarter of 2020. Projected annualized operating expenses excluding cost of goods sold of between $65M-$75M will be achieved by the fourth quarter of 2020. The company expects to book separation and contract termination fees in the fourth quarter and will provide further details during its third quarter financial results webcast and conference call on Tuesday, November 12. The go-forward organization will comprise approximately 120 employees focused on driving the continued growth of ENHANZE, specifically in areas that are critical to supporting partners such as manufacturing, quality, regulatory and product development. An additional 12 employees will continue promoting the company's commercial drug Hylenex. The company's ENHANZE business continues to grow with three commercial products and 11 products currently in clinical trials. Halozyme will provide a more detailed update for its ENHANZE business during its third quarter financial results webcast and conference call. Halozyme's Board of Directors has also authorized the initiation of a capital return program to repurchase up to $350M of the company's outstanding common stock over the next three years. The timing of share repurchases and the number of shares of common stock that are repurchased will depend on market conditions and other factors. Repurchases may be commenced or suspended at any time or from time-to-time at the company's discretion without prior notice. Repurchases may be made through both public market and private transactions. The Board will regularly review this capital return policy in connection with a balanced capital allocation strategy.

07:05 EDT Halozyme says HALO-301 Phase 3 study fails to meet primary endpoint - Halozyme Therapeutics announced that the HALO-301 Phase 3 clinical study evaluating investigational new drug PEGPH20 as a first-line therapy for treatment of patients with metastatic pancreas cancer failed to reach the primary endpoint of overall survival. The treatment arm of PEGPH20 in combination with gemcitabine and nab-paclitaxel failed to demonstrate an improvement in median overall survival compared to gemcitabine and nab-paclitaxel alone. While there was a higher response rate in the PEGPH20 treatment arm, this did not translate into an improvement in duration of response, Progression Free Survival or Overall Survival. "Patients in both treatment arms of the HALO-301 trial surpassed the published median overall survival rates from the pivotal registration study of ABRAXANE plus gemcitabine as first-line therapy for metastatic pancreas cancer, published in 2013. Based on the lack of benefit over standard-of-care in this study, which performed well versus published data, we will be discontinuing PEGPH20 clinical development," said Dr. Helen Torley, president and CEO of Halozyme. "This well-designed and well-executed study did not have the outcome that we or the study participants wanted or expected. I would like to extend a heartfelt thank you to all those who supported and who made this study possible, including the patients who were enrolled, their families, our investigators, their staff, our investors and all of the dedicated Halozyme employees." Halozyme intends to halt development activities for PEGPH20 and implement an organizational restructuring to focus its operations solely on its ENHANZE drug delivery technology.

07:03 EDT Wright Medical to be acquired by Stryker for $30.75 per share in cash - Wright Medical Group (WMGI) announced that it has entered into a definitive agreement under which Stryker (SYK) will acquire all of the issued and outstanding ordinary shares of Wright Medical Group N.V. for a total equity value of approximately $4.7B, including the value of Wright's outstanding convertible notes, and total enterprise value of approximately $5.4B. Under the terms of the agreement, Stryker will commence a tender offer for all outstanding ordinary shares of Wright for $30.75 per share, in cash. The boards of directors of both Stryker and Wright have approved the transaction. The closing of the transaction is subject to receipt of applicable regulatory approvals, the adoption of certain resolutions relating to the transaction at an extraordinary general meeting of Wright's shareholders, completion of the tender offer and other customary closing conditions. The offer of $30.75 per share in cash represents a premium of 52% over the volume-weighted average closing price of Wright ordinary shares over the thirty calendar days ended October 31, 2019, the last trading day prior to speculation that Wright was exploring a sale of the company. The acquisition is expected to close in the second half of 2020. Wright brings a highly complementary product portfolio and customer base to Stryker's trauma and extremities business. With global sales approaching $1B, Wright is a recognized leader in the upper extremities, lower extremities and biologics markets, which are among the fastest growing segments in orthopaedics. Wright's leading upper extremity portfolio and advanced preoperative planning technology will significantly add to Stryker's offering. Additionally, Wright's lower extremity and biologics will complement Stryker's portfolio and strengthen the company's position in this high-growth segment.

07:02 EDT Iberiabank, First Horizon to combine in all-stock merger of equals

06:55 EDT Halozyme trading halted, news pending

06:48 EDT International Game subsidiary signs contract extension with Kentucky Lottery - International Game announced that its subsidiary, IGT Global Solutions, has signed a contract extension with the Kentucky Lottery Corporation for five years through July 9, 2026. The lottery is exercising its five one-year extension options in which IGT will provide new self-service lottery vending machines and updated technology. Under the terms of the extension, IGT will provide the lottery with additional 575 GameTouch 28 self-service vending machines and equip approximately 1,400 total GameTouch 28, GameTouch 20, and GameTouch draw machines with cashless functionality that enables players to use credit or debit cards to purchase lottery products. In addition to these products, IGT provides the Kentucky Lottery with facilities management, field service, call center services and marketing support.

06:34 EDT Cerecor closes sale of pediatric portfolio to Aytu BioScience for $43M - Cerecor (CERC) announced that it has closed the sale of its pediatric portfolio of assets with AYTU BioScience (AYTU) in a deal valued in excess of $43M including the assumption of various liabilities and product-related obligations. The consideration includes a combination of cash and Aytu preferred stock totaling $17M and the assumption of Cerecor's outstanding payment obligations payable to Deerfield CSF in the amount of $15M and certain other liabilities in excess of $11M, providing non-dilutive cash generation for Cerecor. The funds from the transaction, coupled with the removal of the aforementioned short-term obligations, extend the runway toward NDA submission of CERC-801 and its associated Priority Review Voucher. Overall deal valued in excess of $43M as a composite of $17M in cash and preferred stock, the assumption of the Deerfield Note of $15M, the assignment of the existing royalty obligations coupled with various commercial accruals of $11M. Cash has been paid, and the Shares were issued at closing; the Shares are subject to customary lock-ups and are convertible to common shares following Aytu stockholder approval and immediately prior to their sale or distribution.

06:11 EDT Bionomics: FDA Fast Track Designation granted to BNC210 development program - Bionomics announced that the U.S. FDA has granted Fast Track designation to the BNC210 development program for the treatment of Post-Traumatic Stress Disorder and other trauma-related and stressor-related disorders. Bionomics is currently developing a novel solid dose formulation of BNC210 which has recently been shown to achieve the blood levels predicted as necessary to meet the clinical trial primary endpoint for effectiveness for treating PTSD patients; preparations are underway for optimization of the solid dose formulation in anticipation of initiation of a Phase 2b trial in PTSD patients.

06:06 EDT RedHill Biopharma announces FDA approval of Talicia - RedHill Biopharma announced that the U.S. FDA has approved Talicia delayed-release capsules 10 mg/250 mg/12.5 mg for the treatment of Helicobacter pylori infection in adults. RedHill expects to launch Talicia in the U.S. in the first quarter of 2020 with its dedicated sales force. Talicia is the only rifabutin-based therapy approved for the treatment of H. pylori infection and is designed to address the high resistance of H. pylori bacteria to current clarithromycin-based standard-of-care therapies. It is estimated that H. pylori resistance to clarithromycin more than doubled between 2009-2013.

06:04 EDT Aphria doubles production capacity after receiving cultivation licence - Aphria announced it has received a cultivation licence from Health Canada for Aphria Diamond, the company's second Leamington, Ontario cannabis greenhouse facility, bringing an additional 1,300,000 square feet of production space with an annual growing capacity of 140,000kg. Combined with the company's Aphria One facility and its subsidiary Broken Coast Cannabis, the Company now has more than 2,400,000 square feet of cultivation space capable of reaching a total annualized production capacity of 255,000kg.

05:45 EDT Under Armour says cooperating with DOJ, SEC accounting investigations - Under Armour said last night in a statement to CNBC: "Under Armour is cooperating with the U.S. Securities and Exchange Commission and the U.S. Department of Justice investigations. The company began responding in July 2017 to requests for documents and information relating primarily to its accounting practices and related disclosures, and the company firmly believes that its accounting practices and disclosures were appropriate." Shares of Under Armour (UAA) are down 16%, or $3.43, to $17.71 in premarket trading. Reference Link

05:23 EDT Amazon expands delivery options during holiday season - With the holiday season officially underway, Amazon has expanded its fast, free, and convenient delivery options. "From Los Angeles, California and Killeen, Texas to Elkhart, Indiana and Philadelphia, Pennsylvania, Prime members across the U.S. now have access to over 10 million items available for delivery the next day for free, including popular holiday gifts such as toys, games, and electronics. Amazon has also expanded its Prime Free Same-Day Delivery, bringing the convenience of doorstep delivery within hours to millions more members since last holiday season. This is in addition to free shipping on millions of items that all customers can enjoy year-round on orders over $25."